Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record.

Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

Buckingham, Robin E, Al-Barazanji, Kamal A, Toseland, C D Nigel, Slaughter, Mark, Connor, Susan C, West, Andrew, Bond, Brian, Turner, Nicholas C, Clapham, John C·1998·Diabetes

Abstract

Rosiglitazone (BRL 49653), a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and potent insulin action-enhancing agent, was given in the diet (50 umol/kg of diet) to male Zucker rats ages 6–7 weeks for 9 months (prevention group). In this treatment mode, rosiglitazone prolonged the time to onset of proteinuria from 3 to 6 months and markedly reduced the rate of its subsequent progression. Progression was also retarded when treatment was commenced (intervention group) after proteinuria had become established (4 months; ages 24–25 weeks). In either treatment mode, rosiglitazone normalized urinary N-acetyl-β-D-glucosaminidase activity, a marker for renal proximal tubular damage, and ameliorated the rise in systolic blood pressure that occurred coincidentally with the development of proteinuria in Zucker fatty control rats. The renal protective action of rosiglitazone was verified morphologically. Thus in the prevention group there was an absence of the various indexes of chronic nephropathy that were prominent in the Zucker fatty control group, namely, glomerulosclerosis, dilated tubules containing proteinaceous casts, a loss of functional microvilli on the tubular epithelium, and varying degrees of chronic interstitial nephritis. An intermediate pathology was observed in the intervention group. Also, pancreatic islet hyperplasia, ultrastructural evidence of (β-cell work hypertrophy, and derangement of α-cell distribution within the islet were prominent features of Zucker fatty control rats, but these adaptive changes were ameliorated (intervention group) or prevented (prevention group) by rosiglitazone treatment. These data demonstrate that treatment of Zucker fatty rats with rosiglitazone produced substantial protection over a prolonged period against the development and progression of renal injury and the adaptive changes to pancreatic islet morphology caused by sustained hyperinsulinemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diab.47.8.1326

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 203

Metadata

Authors
Buckingham, R. E., Al-Barazanji, K. A., Toseland, C. D. N., Slaughter, M., Connor, S. C., West, A., Bond, B., Turner, N. C., & Clapham, J. C.
Venue
Diabetes
Published
1998-08-01
Volume
47
Issue
8
Pages
1326-1334
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2101329987
Cited by
203
References
0
FWCI
3.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats. https://app.cochat.ai/papers/10.2337/diab.47.8.1326
The paper
Buckingham, R. E., Al-Barazanji, K. A., Toseland, C. D. N., Slaughter, M., Connor, S. C., West, A., Bond, B., Turner, N. C., & Clapham, J. C. (1998). Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats. Diabetes. https://doi.org/10.2337/diab.47.8.1326

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.